Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 208

Results For "24"

2125 News Found

PLI Scheme to generate export potential of Rs 196,000 crore by 2027 : Mandaviya
Policy | August 03, 2021

PLI Scheme to generate export potential of Rs 196,000 crore by 2027 : Mandaviya

The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales


Abbott's Freestyle Libre 2 Ios App Cleared In U.S
Drug Approval | August 03, 2021

Abbott's Freestyle Libre 2 Ios App Cleared In U.S

FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms


API exports surpass imports by value in 2020-21
Policy | August 03, 2021

API exports surpass imports by value in 2020-21

The govt has rolled out three schemes for promoting the manufacture of API


Glenmark signs agreement with SaNOtize to manufacture NONS
News | August 02, 2021

Glenmark signs agreement with SaNOtize to manufacture NONS

The Phase III clinical trial for NONS is expected to be completed by Q4 2021.


Ajanta Pharma aims to file 10-12 ANDAs per annum
News | August 02, 2021

Ajanta Pharma aims to file 10-12 ANDAs per annum

India business is growing as per projections; whereas US business will bounce back soon.


Granules India earmarks Rs 400 crore as Capex for FY 22
News | August 02, 2021

Granules India earmarks Rs 400 crore as Capex for FY 22

The company has an outlay of Rs 120-140 crore as R & D expense for FY 22


Sun Pharmaceutical Industries Q1FY22 consolidated PAT soars to Rs. 1408.65 Cr
News | July 31, 2021

Sun Pharmaceutical Industries Q1FY22 consolidated PAT soars to Rs. 1408.65 Cr

It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.


Pfizer posts Q1FY22 PAT of Rs. 199.91 Cr
News | July 29, 2021

Pfizer posts Q1FY22 PAT of Rs. 199.91 Cr

The company posted net profit of Rs.124.45 crores for the period ended June 30, 2020.


Bharat Immunologicals and Biologicals Corporation Q1FY22 net profit at Rs. 1.92 Cr
News | July 28, 2021

Bharat Immunologicals and Biologicals Corporation Q1FY22 net profit at Rs. 1.92 Cr

The company reported total income Rs.18.57 crores during the period ended June 30, 2020.


Torrent Pharmaceuticals Q1FY22 consolidated PAT up at Rs. 330 Cr
News | July 28, 2021

Torrent Pharmaceuticals Q1FY22 consolidated PAT up at Rs. 330 Cr

The company posted net profit of Rs.321 crores for the period ended June 30, 2020.